Xu, Jing

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 255

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

Xu, J., Pfarr, N., Endris, V, Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., et al. (2017) · Oncogenesis

Multiple Myeloma Research and TreatmentsMelanoma and MAPK Pathways

Cited by 89

Can one or two simple questions predict poor medication adherence?

Stuart, B. C., Timmons, V., Loh, F. E., Dai, M., & Xu, J. (2021) · Journal of Evaluation in Clinical Practice

Medication Adherence and ComplianceDiabetes Management and Education

Cited by 2